Circulating Tumor DNA—the Potential of Liquid Biopsies

Karen Cravero, Ben Ho Park

Research output: Contribution to journalArticlepeer-review

Abstract

Recent studies suggest circulating cell-free tumor DNA offers advantages compared to tissue biopsies for mutation profiling. This concept of “liquid biopsy” allows for a more global genomic picture of metastatic disease since blood serves as a reservoir for all metastatic sites. In addition, cell-free tumor DNA can be measured quantitatively, presenting the possibility of using circulating tumor DNA as a biomarker to measure disease burden and response to therapies. Here, we review historic and recent studies demonstrating the clinical potential of measuring cell-free tumor DNA in breast cancer patients and future steps needed to translate liquid biopsies from research to clinical practice.

Original languageEnglish (US)
Pages (from-to)14-21
Number of pages8
JournalCurrent Breast Cancer Reports
Volume8
Issue number1
DOIs
StatePublished - Mar 1 2016

Keywords

  • Breast cancer
  • Circulating tumor DNA
  • Liquid biopsy
  • Mutation
  • Plasma tumor DNA
  • Translational research

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Circulating Tumor DNA—the Potential of Liquid Biopsies'. Together they form a unique fingerprint.

Cite this